eMedicine Specialties > Pediatrics: General Medicine > Nephrology

Oliguria: Differential Diagnoses & Workup

Author: Prasad Devarajan, MD, Louise M Williams Endowed Chair in Pediatrics, Professor of Pediatrics and Developmental Biology, Director of Nephrology and Hypertension, Director of Clinical Nephrology Laboratories, Chief Executive Officer of Dialysis Unit, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine
Contributor Information and Disclosures

Updated: Dec 3, 2008

Workup

Laboratory Studies

The following studies are indicated in patients with oliguria:

  • Urinalysis
    • Careful examination of a freshly voided urine sample is a rapid and inexpensive way of distinguishing prerenal from intrinsic renal failure.
    • In prerenal failure, a few hyaline and fine granular casts may be observed with little protein, heme, or red cells. Heme-positive urine in the absence of erythrocytes suggests hemolysis or rhabdomyolysis.
    • In intrinsic renal failure, hematuria and proteinuria are prominent. Broad brown granular casts are typically found in ischemic or toxic acute tubular necrosis, and red cell casts are characteristically observed in acute glomerulonephritis. The urine in acute interstitial nephritis shows white cells, especially eosinophils and white cell casts.
  • Urinary indexes
    • Simultaneous measurement of urinary and serum sodium, creatinine, and osmolality can help differentiate between prerenal azotemia, in which the reabsorptive capacity of tubular cells and concentrating ability of the kidney are preserved or even enhanced, and intrinsic renal failure, in which these functions are impaired because of structural damage.
    • In prerenal failure, urine specific gravity is high (>1020), the ratio of urinary to plasma creatinine is high (>40), the ratio of urinary to plasma osmolality is high (>1.5), and the urinary sodium concentration is low (<20 mEq/L).
    • In intrinsic renal failure, the opposite findings are encountered, which are a urine–to–plasma creatinine ratio less than 20, a urine–to–plasma osmolality ratio less than 1.1, and urine sodium concentration greater than 40 mEq/L.
    • The fractional excretion of sodium (FENa) is the percentage of filtered sodium that is excreted. It is easily calculated by the formula: %FENa = [(U/P)Na]/[(U/P)Cr] X 100, where Na and Cr represent the concentrations of sodium and creatinine in the urine (U) and plasma (P), respectively. The %FENa is typically less than 1% in prerenal azotemia and greater than 2% in intrinsic renal failure.
    • Interpretation of urinary indexes requires caution. Blood and urine specimens should be collected before the administration of fluids, mannitol, or diuretics. The urine should be free of glucose, contrast material, or myoglobin. Urinary indexes suggestive of prerenal failure (eg, %FENa <1, urinary sodium <20 mEq/L) can also be encountered in early glomerulonephritis, vasculitis and vascular occlusion, early postrenal failure, contrast nephropathy, and rhabdomyolysis. Also, the FENa may be falsely elevated in patients with prerenal failure and with increased urinary excretion of ketoacids or glucose.
  • BUN and serum creatinine
    • In prerenal failure, elevation of BUN levels is marked and the BUN-to-Cr ratio is greater than 20. This reflects increased proximal tubular reabsorption of urea. The hallmark of established acute renal failure is a daily increase in serum creatinine (0.5-1.5 mg/dL/d) levels and in BUN (10-20 mg/dL/d) levels.
    • Elevations in BUN levels can also result from steroid therapy, parenteral nutrition, GI bleeding, and catabolic states. A spurious elevation in serum creatinine can be encountered following the use of drugs that interfere with the tubular secretion of creatinine (eg, trimethoprim, cimetidine) or drugs that provide chromogenic substrates (eg, cephalosporins), which interfere with the Jaffé reaction for determination of serum creatinine.
    • Although serum creatinine levels are the criterion standard for diagnosis of acute renal failure, they remain an unreliable indicator during acute changes in kidney function for the following reasons: 
      • Serum creatinine levels can widely vary with age, gender, lean muscle mass, muscle metabolism, and hydration status. 
      • Serum creatinine levels may not change until about 50% of kidney function has already been lost. 
      • At lower rates of glomerular filtration, the amount of tubular secretion of creatinine results in overestimation of renal function. 
      • During acute changes in glomerular filtration, serum creatinine levels do not accurately depict kidney function until steady state equilibrium has been reached, which may require several days. 
    • In the future, defining acute renal failure by either a predictive biomarker of kidney damage or a sensitive measure of decrease in kidney function may be possible. Fortunately, the tools of modern science offer promising novel biomarkers for the early diagnosis of acute renal failure and its clinical outcomes.3  These biomarkers are currently undergoing evaluation and validation and are not yet commercially available.
  • Serum sodium
    • Hyponatremia is a common finding that is usually dilutional, secondary to fluid retention and administration of hypotonic fluids.
    • Less common causes of hyponatremia include sodium depletion (hyponatremic dehydration) and hyperglycemia (serum sodium concentration decreases by 1.6 mEq/L for every 100 mg/dL increase in serum glucose above 100 mg/dL). Occasionally, hypernatremia may complicate oliguric acute renal failure and is usually a result of excessive sodium administration (improper fluid administration or overzealous sodium bicarbonate therapy).
  • Serum potassium
    • Hyperkalemia is an important complication because of reduced glomerular filtration, reduced tubular secretion, metabolic acidosis (each 0.1-unit reduction in arterial pH raises serum potassium by 0.3 mEq/L), and associated catabolic state.
    • Hyperkalemia is most pronounced in patients with excessive endogenous potassium production, which occurs in rhabdomyolysis, hemolysis, and tumor lysis syndrome.
    • Hyperkalemia represents a life-threatening emergency that must be promptly and aggressively treated, primarily because of its depolarizing effect on cardiac conduction pathways.
    • Symptoms may include malaise, nausea, and muscle weakness.
  • Serum phosphate and calcium
    • Hyperphosphatemia and hypocalcemia frequently complicate oliguric acute renal failure. The phosphate excess is secondary to reduced renal excretion and can result in hypocalcemia and calcium phosphate deposition in various tissues.
    • Hypocalcemia results from hyperphosphatemia-impaired gastrointestinal calcium absorption because of inadequate active vitamin D production by the kidney, skeletal resistance to the calcemic action of parathyroid hormone, and coexistent hypoalbuminemia.
    • Determining ionized calcium levels is important because this unbound form of serum calcium determines physiologic activity. Ionized calcium can be estimated by assuming that 1 mg/dL of calcium is bound to 1 g/dL of albumin; thus, ionized calcium is the difference between total calcium and serum albumin concentration.
    • Acidosis increases the fraction of total calcium in the ionized form; thus, overzealous bicarbonate therapy can decrease ionized calcium.
    • Severe hypocalcemia results in tetany, seizures, and cardiac arrhythmias
  • Acid-base balance
    • The impaired renal excretion of nonvolatile acids and decreased tubular reabsorption and regeneration of bicarbonate results in metabolic acidosis with a high anion gap.
    • Severe acidosis can develop in children who are hypercatabolic (eg, shock, sepsis) or who have inadequate respiratory compensation.
    • The last 2 digits of the arterial pH provide a bedside estimate of respiratory compensation. Those numbers predict the pCO2 (eg, a patient with arterial pH of 7.25 has adequate respiratory compensation if the arterial pCO2 is 25 ± 3 mm Hg).
  • CBC count
    • Anemia is a result of dilution and decreased erythropoiesis. Microangiopathic hemolytic anemia with schistocytes and thrombocytopenia are indicative of hemolytic-uremic syndrome.
    • Patients with oliguria that is secondary to systemic lupus erythematosus may display neutropenia and thrombocytopenia.
    • Eosinophilia is consistent with allergic interstitial nephritis.
    • Prolonged acute renal failure can result in functional platelet disorders.
  • Serologic tests
    • Additional laboratory studies should be performed as indicated.
    • Decreased complement levels (C3, C4) are characteristic of acute poststreptococcal glomerulonephritis but can also be observed in lupus nephritis and membranoproliferative glomerulonephritis. A suspected diagnosis of acute poststreptococcal glomerulonephritis can be confirmed by detection of elevated antistreptococcal titers. The presence of antinuclear antibodies is suggestive of lupus nephritis, and antineutrophil cytoplasmic antibodies indicate vasculitis.

Imaging Studies

  • Renal ultrasonography
    • Ultrasonography of the kidneys and bladder with Doppler flow studies is essential.
    • Exceptions may include children with unmistakable prerenal failure from dehydration who promptly respond to fluid resuscitation or those with mild renal insufficiency secondary to a nephrotoxin who respond to discontinuing the medication.
    • Ultrasonography provides important information regarding kidney size and echogenicity, renal blood flow, collecting system, and bladder wall.
    • Children with acute intrinsic renal failure display echogenic kidneys that may be enlarged. With prolonged renal failure, renal cortical necrosis may result in decreased kidney size. Bilaterally small and scarred kidneys are indicative of chronic renal disease. Congenital disorders, such as polycystic kidney disease and multicystic dysplasia, are easily detected. Calculi and tumors that can cause obstruction may also be detected.
    • A Doppler study is critical in the evaluation of vascular obstruction. Hydronephrosis, hydroureter, and a thickened bladder wall are consistent with obstruction of the bladder outlet or below.
  • Other imaging studies
    • Voiding cystourethrography is indicated with suspected bladder outlet obstruction.
    • Radionuclide renal scanning may be useful in the assessment of transplant rejection and obstruction.
    • Chest radiography may be indicated if pulmonary edema is suspected.
    • Echocardiography may be useful in the presence of congestive heart failure.

Other Tests

  • Electrocardiography
    • This test is indicated if hyperkalemia is suspected or detected by laboratory tests.
    • The earliest sign is the appearance of tall peaked T waves. Recognizing and treating hyperkalemia at this early stage is important.
    • Subsequent findings include the following:
      • Prolongation of the PR interval
      • Flattening of P waves
      • Widening of QRS complexes
      • ST segment changes
      • Ventricular tachycardia
      • Terminal ventricular fibrillation

Procedures

  • Renal biopsy
    • In general, kidney biopsy is not necessary in the initial evaluation; however, if prerenal and postrenal causes have been ruled out and an intrinsic renal disease other than prolonged ischemia, nephrotoxin, or postinfectious glomerulonephritis is suspected, renal biopsy may be valuable in establishing diagnosis, guiding therapy, and providing prognosis.
    • Histologic examination is especially valuable in the diagnosis and management of transplant rejection, rapidly progressive glomerulonephritis, lupus nephritis, and tubulointerstitial nephritis.

Histologic Findings

Histology depends on the underlying cause. Only ischemic and nephrotoxic acute tubular necroses are discussed.

  • In human ischemic acute tubular necrosis, frank tubule cell necrosis is rarely encountered. Instead, the prominent morphologic features include effacement and loss of proximal tubule brush border, patchy loss of tubule cells, focal areas of proximal tubular dilatation and distal tubular casts, and areas of cellular regeneration. Necrosis is inconspicuous and restricted to the highly susceptible outer medullary regions of the kidney. The glomeruli are usually unimpressive, unless a primary glomerular disease had caused the oliguria. This apparent disparity between the severe impairment of renal function and the relatively subtle histologic changes has traditionally been puzzling.
  • More recently, however, reconciliation has been forthcoming from a consistent finding of apoptotic cell death in both distal and proximal tubules in both ischemic and nephrotoxic forms of intrinsic renal failure In addition, a great deal of attention has been directed toward the peritubular capillaries, which display striking vascular congestion, endothelial damage, and leukocyte accumulation.
  • In contrast, in nephrotoxic acute tubular necrosis, the findings on light microscopy are generally characterized by more extensive and uniform tubular necrosis. Most of the proximal tubules display necrotic cell death, desquamation, and dilatation. A moderately severe interstitial edema may be observed. The glomeruli appear normal. Morphologically, several leukocyte subtypes have been shown to aggregate in peritubular capillaries, interstitial space, and even within tubules following ischemic acute renal failure, and their relative roles remain under investigation. Neutrophils are the earliest leukocytes to accumulate in the postischemic kidney.

More on Oliguria

Overview: Oliguria
Differential Diagnoses & Workup: Oliguria
Treatment & Medication: Oliguria
Follow-up: Oliguria
Multimedia: Oliguria
References

References

  1. Bunchman TE, McBryde KD, Mottes TE, et al. Pediatric acute renal failure: outcome by modality and disease. Pediatr Nephrol. Dec 2001;16(12):1067-71. [Medline].

  2. Hui-Stickle S, Brewer ED, Goldstein SL. Pediatric ARF epidemiology at a tertiary care center from 1999 to 2001. Am J Kidney Dis. Jan 2005;45(1):96-101. [Medline].

  3. Parikh CR, Devarajan P. New biomarkers of acute kidney injury. Crit Care Med. Apr 2008;36(4 Suppl):S159-65. [Medline].

  4. Gambaro G, Bertaglia G, Puma G, D'Angelo A. Diuretics and dopamine for the prevention and treatment of acute renal failure: a critical reappraisal. J Nephrol. May-Jun 2002;15(3):213-9. [Medline].

  5. Cantarovich F, Rangoonwala B, Lorenz H, et al. High-dose furosemide for established ARF: a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Am J Kidney Dis. Sep 2004;44(3):402-9. [Medline].

  6. Abuelo JG. Normotensive ischemic acute renal failure. N Engl J Med. Aug 23 2007;357(8):797-805. [Medline].

  7. American Society of Nephrology. American Society of Nephrology Renal Research Report. J Am Soc Nephrol. Jul 2005;16(7):1886-903. [Medline][Full Text].

  8. Andreoli SP. Acute renal failure. Curr Opin Pediatr. Apr 2002;14(2):183-8. [Medline].

  9. Bellomo R, Ronco C, Kellum JA, et al. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. Aug 2004;8(4):R204-12. [Medline][Full Text].

  10. Bonventre JV, Zuk A. Ischemic acute renal failure: an inflammatory disease?. Kidney Int. Aug 2004;66(2):480-5. [Medline].

  11. Chertow GM, Burdick E, Honour M, et al. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol. Nov 2005;16(11):3365-70. [Medline].

  12. Devarajan P. Cellular and molecular derangements in acute tubular necrosis. Curr Opin Pediatr. Apr 2005;17(2):193-9. [Medline].

  13. Devarajan P. Update on mechanisms of ischemic acute kidney injury. J Am Soc Nephrol. Jun 2006;17(6):1503-20. [Medline].

  14. Devarajan P, Goldstein SL. Acute renal failure. In: Kher KK, Schnaper HW, Makker SP. Clinical Pediatric Nephrology. Second Edition. Oxon, UK: Informa Healthcare; 2007:3770390.

  15. Friedewald JJ, Rabb H. Inflammatory cells in ischemic acute renal failure. Kidney Int. Aug 2004;66(2):486-91. [Medline].

  16. Goldstein SL. Pediatric acute kidney injury: it's time for real progress. Pediatr Nephrol. Jul 2006;21(7):891-5. [Medline].

  17. Goldstein SL. Pediatric acute renal failure: demographics and treatment. Contrib Nephrol. 2004;144:284-90. [Medline].

  18. Gouyon JB, Guignard JP. Management of acute renal failure in newborns. Pediatr Nephrol. Sep 2000;14(10-11):1037-44. [Medline].

  19. Klahr S, Miller SB. Acute oliguria. N Engl J Med. Mar 5 1998;338(10):671-5. [Medline].

  20. Lameire N, Van Biesen W, Vanholder R. Acute renal failure. Lancet. Jan 29-Feb 4 2005;365(9457):417-30. [Medline].

  21. Lameire NH, De Vriese AS, Vanholder R. Prevention and nondialytic treatment of acute renal failure. Curr Opin Crit Care. Dec 2003;9(6):481-90. [Medline].

  22. Mehta RL, Chertow GM. Acute renal failure definitions and classification: time for change?. J Am Soc Nephrol. Aug 2003;14(8):2178-87. [Medline][Full Text].

  23. Mehta RL, Pascual MT, Soroko S, et al. Spectrum of acute renal failure in the intensive care unit: the PICARD experience. Kidney Int. Oct 2004;66(4):1613-21. [Medline].

  24. Molitoris BA, Sutton TA. Endothelial injury and dysfunction: role in the extension phase of acute renal failure. Kidney Int. Aug 2004;66(2):496-9. [Medline].

  25. Perico N, Cattaneo D, Sayegh MH, Remuzzi G. Delayed graft function in kidney transplantation. Lancet. Nov 13-19 2004;364(9447):1814-27. [Medline].

  26. Rabb H, Colvin RB. Case records of the Massachusetts General Hospital. Case 31-2007. A 41-year-old man with abdominal pain and elevated serum creatinine. N Engl J Med. Oct 11 2007;357(15):1531-41. [Medline].

  27. Racusen LC. The morphologic basis of acute renal failure. In: Molitoris BA, Finn WF, eds. Acute Renal Failure. Philadelphia, PA: WB Saunders; 2004:1-12.

  28. Safirstein RL. Acute renal failure: from renal physiology to the renal transcriptome. Kidney Int Suppl. Oct 2004;S62-6. [Medline].

  29. Schrier RW. Need to intervene in established acute renal failure. J Am Soc Nephrol. Oct 2004;15(10):2756-8. [Medline][Full Text].

  30. Schrier RW, Wang W. Acute renal failure and sepsis. N Engl J Med. Jul 8 2004;351(2):159-69. [Medline].

  31. Schrier RW, Wang W, Poole B, Mitra A. Acute renal failure: definitions, diagnosis, pathogenesis, and therapy. J Clin Invest. Jul 2004;114(1):5-14. [Medline][Full Text].

  32. Siegel NJ, Van Why SK, Devarajan P. Pathogenesis of acute renal failure. In: Avner ED, Harmon WE, Niaudet P, eds. Pediatric Nephrology. Philadelphia, PA: Lippincott Williams & Wilkins; 2004:1223.

  33. Star RA. Treatment of acute renal failure. Kidney Int. Dec 1998;54(6):1817-31. [Medline].

  34. Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA. Aug 17 2005;294(7):813-8. [Medline].

  35. Warnock DG. Towards a definition and classification of acute kidney injury. J Am Soc Nephrol. Nov 2005;16(11):3149-50. [Medline].

Further Reading

Keywords

oliguria, acute renal failure, ARF, prerenal failure, small amount of urine, kidney disease, obstruction of the urinary tract, impaired renal function, nephrotoxins, interstitial nephritis, neonatal asphyxia, dehydration, renal hypoperfusion, acute tubular necrosis, hemolytic uremic syndrome, sepsis, bone marrow transplantation, renal insufficiency, diarrhea, diabetes insipidus, diabetes mellitus, nephrotic syndrome, streptococcal infection, postinfectious glomerulonephritis, systemic lupus erythematosus, sinusitis, Wegener granulomatosis, Goodpasture disease, hematuria, proteinuria, hypertension, hepatomegaly, gallop rhythm, pulmonary edema, encephalopathy, Henoch-Schönlein purpura, renal vein thrombosis, polycystic kidneys, multicystic dysplasia, hydronephrosis, respiratory distress syndrome, bladder outlet obstruction, neurogenic bladder, ureteral obstruction, salt-wasting nephropathy

Contributor Information and Disclosures

Author

Prasad Devarajan, MD, Louise M Williams Endowed Chair in Pediatrics, Professor of Pediatrics and Developmental Biology, Director of Nephrology and Hypertension, Director of Clinical Nephrology Laboratories, Chief Executive Officer of Dialysis Unit, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine
Prasad Devarajan, MD is a member of the following medical societies: American Heart Association, American Society of Nephrology, American Society of Pediatric Nephrology, National Kidney Foundation, and Society for Pediatric Research
Disclosure: Nothing to disclose.

Medical Editor

Laurence Finberg, MD, Clinical Professor, Department of Pediatrics, University of California at San Francisco and Stanford University
Laurence Finberg, MD is a member of the following medical societies: American Medical Association
Disclosure: Nothing to disclose.

Pharmacy Editor

Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine
Disclosure: Pfizer Inc Stock Investment from broker recommendation; Avanir Pharma Stock Investment from broker recommendation

Managing Editor

Luther Travis, MD, William W Glauser Professor of Pediatrics and Pediatric Nephrology, Department of Pediatrics, Divisions of Nephrology and Diabetes, University of Texas Medical Branch and Children's Hospital
Luther Travis, MD is a member of the following medical societies: Alpha Omega Alpha, American Federation for Medical Research, International Society of Nephrology, and Texas Pediatric Society
Disclosure: Nothing to disclose.

CME Editor

Howard Trachtman, MD, Program Director, Pediatrics Research, Schneider Children's Hospital, Department of Pediatrics, Division of Nephrology, Professor, Albert Einstein College of Medicine
Howard Trachtman, MD is a member of the following medical societies: American Society of Hypertension, American Society of Nephrology, American Society of Pediatric Nephrology, and Society for Pediatric Research
Disclosure: Nothing to disclose.

Chief Editor

Craig B Langman, MD, The Isaac A Abt, MD, Professor of Kidney Diseases, Feinberg School of Medicine, Northwestern University; Division Head of Kidney Diseases, Children's Memorial Hospital, Chicago
Craig B Langman, MD is a member of the following medical societies: American Academy of Pediatrics, American Society of Nephrology, and International Society of Nephrology
Disclosure: Amgen Grant/research funds None; Abbott Honoraria Speaking and teaching; Altus Pharmaceuticals Grant/research funds None; Genzyme Grant/research funds None; Merck Grant/research funds None; NIH Grant/research funds None

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.